Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview

Rhea-AI Summary

Exousia Pro (OTC PINK:MAJI) has shared significant findings regarding their Glioblastoma (GBM) study. Chief Science Officer Dr. Marvin Hausman revealed in a Spaces interview that published research demonstrates the effectiveness of NANOG Expression therapy in treating GBM cells.

The research showed that while temozolomide (TMZ) alone at maximum concentration eliminated less than 20% of GBM cells, combining TMZ with shRNA targeting NANOG or OCT4 significantly increased cell death rates. This combination therapy proved particularly effective at reducing the resistance of Cancer stem cells in Glioblastoma.

Positive

• Published research validates the effectiveness of company's NANOG Expression therapy
• Significant improvement in cancer cell death rates when combining NANOG/OCT4 targeting with traditional treatment
• Technology shows promise in overcoming resistance in Glioblastoma treatment

Negative

• None.

A published paper shows NANOG Expression was almost 100% effective at eradicating tumor cells

ORLANDO, FL / ACCESS Newswire / April 21, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to share published information about the therapy being used in our current Glioblastoma ("GBM") study.

Dr. Marvin Hausman, our Chief Science Officer, revealed Thursday live on a Spaces interview that a paper had been published showing that the NANOG Expression therapy reduced the resistance of the Cancer stem cells in Glioblastoma. In fact, the paper goes on to reveal that when temozolomide ("TMS") was used on its own at its highest concentration, less than 20% of the GBM cells were killed. When the GBM cells were treated with shRNA targeting NANOG or OCT4 in combination with TMZ, the level of cell death was significantly higher compared to that of the TMZ treatment alone, suggesting that the inhibition of NANOG or OCT4 increased the efficacy of TMZ.

The full paper may be read here: https://pmc.ncbi.nlm.nih.gov/articles/PMC10297980/

Matt Dwyer, our President, stated, "I was listening to the Spaces interview and couldn't believe what I was hearing. I had no clue this information existed. I know the current study and its findings, but this was mind-blowing. I suggest everyone go listen to Dr. Hausman and pay attention to the excitement in his voice as he discusses the ongoing study."

About Us

Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.

For more information, please visit: www.exousiapro.com

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro

Investor Relations
ir@exousiapro.com

SOURCE: Marijuana Inc.

View the original press release on ACCESS Newswire

FAQ

What are the key findings of MAJI's Glioblastoma treatment study?

The study showed that combining NANOG Expression therapy with temozolomide (TMZ) significantly increased GBM cell death compared to TMZ treatment alone, which only killed less than 20% of cells.

How effective is MAJI's NANOG Expression therapy for Glioblastoma treatment?

When combined with TMZ, the NANOG Expression therapy significantly reduced cancer stem cell resistance in Glioblastoma, showing higher efficacy than traditional TMZ treatment alone.

What is the mechanism behind MAJI's Glioblastoma treatment?

The treatment uses shRNA targeting NANOG or OCT4 in combination with temozolomide (TMZ), which increases the effectiveness of TMZ in killing Glioblastoma cells.

What progress has MAJI made in their clinical-stage Glioblastoma research?

MAJI has published research demonstrating that their combination therapy approach using NANOG Expression significantly enhances the effectiveness of traditional Glioblastoma treatments.